Validation of a New Automated Renin Assay

Freie Universität Berlin, Berlín, Berlin, Germany
Clinical Chemistry (Impact Factor: 7.91). 12/2004; 50(11):2111-6. DOI: 10.1373/clinchem.2004.032052
Source: PubMed


Measurement of plasma renin is important for the treatment of patients with congenital adrenal hyperplasia (CAH) and in the evaluation of patients with suspected hyperaldosteronism. Immunologic assays for plasma renin offer easier implementation and standardization than enzyme-kinetic assays for plasma renin activity, but their sensitivity and specificity have been questioned. We studied a renin immunochemiluminescence assay on an automated platform.
Renin was measured by an enzymatic assay, by IRMA, and by the new Nichols Advantage Specialty System immunochemiluminometric assay (ICMA), in plasmas from unselected individuals from our outpatient departments and in samples from patients with selected diagnoses.
The detection limit in the ICMA was 0.1 mU/L. The recovery was >90%, and the imprecision (CV) was generally <9%. Mean (SD) concentrations measured by ICMA were 32 (21)% lower than those measured by IRMA. Renin concentrations as measured by ICMA were identical in serum and EDTA-, heparin-, and citrate-anticoagulated plasmas. Prolonged incubation of whole blood at room temperature before centrifugation did not affect renin concentrations. The central 95% interval for 80 healthy adults was 6-85.5 mU/L. Plasma renin as assessed by ICMA in patients with primary hyperaldosteronism was <0.2 mU/L.
The performance characteristics of the new renin ICMA allow its use for patients with CAH and for the diagnosis of mineralocorticoid hypertension. In view of the variability of renin concentrations, use for other forms of hypertension or physiologic research calls for the development of uniform sampling protocols.


Available from: Jaap Deinum, Dec 27, 2013
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper looks at the notion of safety assessment supporting research as developed by the Institute for Nuclear Safety and Protection in the human factor domain. Firstly, the authors list the main issues identified when assessing the safety of computerised procedures from the human factor point of view. They then present the methodology used to gather and analyse data in an attempt to derive further into the issues by means of research. The approach presented consists of trying to describe and understand the cognitive activity of the operators when they are operating a nuclear unit using a computerised procedure. The first results from this research are illustrated through an example
    Human Factors and Power Plants, 1997. 'Global Perspectives of Human Factors in Power Generation'., Proceedings of the 1997 IEEE Sixth Conference on; 07/1997
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The ratio of plasma aldosterone concentration to plasma renin activity (PAC/PRA) is the most common screening test for primary hyperaldosteronism (PHA), but it is not standardized among laboratories. We evaluated new automated assays for the simultaneous measurement of PAC and plasma renin concentration (PRC). We studied 76 healthy normotensive volunteers and 28 patients with confirmed PHA. PAC and PRC were measured immunochemically in EDTA plasma on the Nichols Advantage chemiluminescence analyzer, and PRA was determined by an activity assay. In volunteers, PAC varied from 33.3 to 1930 pmol/L, PRA from 1.13 to 19.7 ng.mL(-1).h(-1) (0.215 ng.mL(-1).h(-1) = 1 pmol.L(-1).s(-1)), and PRC from 5.70 to 116 mU/L. PAC/PRA ratios ranged from 4.35 to 494 (pmol/L)/(ng.mL(-1).h(-1)) and PAC/PRC ratios from 0.69 to 71.0 pmol/mU. In PHA patients, PAC ranged from 158 to 5012 pmol/L, PRA from 0.40 to 1.70 ng.mL(-1).h(-1), and PRC from 0.80 to 11.7 mU/L. PAC/PRA ratios were between 298 and 6756 (pmol/L)/(ng.mL(-1).h(-1)) and PAC/PRC ratios between 105 and 2328 pmol/mU. Whereas PAC or PRC showed broad overlap between PHA patients and volunteers, the PAC/PRC ratio indicated distinct discrimination of these two groups at a cutoff of 71 pmol/mU. The PAC/PRC ratio offers several practical advantages compared with the PAC/PRA screening method. The present study offers preliminary evidence that it may be a useful screening test for PHA. Further studies are required to validate these results, especially in hypertensive cohorts.
    Clinical Chemistry 10/2004; 50(9):1650-5. DOI:10.1373/clinchem.2004.033159 · 7.91 Impact Factor
  • Source

    Journal of Renin-Angiotensin-Aldosterone System 01/2006; 6(3):163-5. DOI:10.3317/jraas.2005.025 · 2.40 Impact Factor
Show more